NYSE:CBM

Cambrex (CBM) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$59.99
$59.99
50-Day Range
$59.99
$59.99
52-Week Range
$33.80
$60.29
Volume
N/A
Average Volume
218,726 shs
Market Capitalization
$2.02 billion
P/E Ratio
21.66
Dividend Yield
N/A
Price Target
N/A
CBM stock logo

About Cambrex Stock (NYSE:CBM)

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

CBM Stock News Headlines

China CBM Group Co Ltd 08270
Cambrex Announces Sale of Drug Product Business Unit
CBM_old Historical Data
Cleantech Building Materials: Result of General Meeting
Cleantech Building Materials: Notice of General Meeting
Cambrex Announces Stability Storage Expansions in Ireland and Belgium
Cambrex finishes first phase of expansion - Yahoo News
See More Headlines
Receive CBM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cambrex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/02/2018
Today
5/16/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Life Sciences Tools & Services
CUSIP
13201110
Fax
N/A
Employees
1,732
Year Founded
N/A

Profitability

Net Income
$92.41 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$532.09 million
Cash Flow
$3.91 per share
Book Value
$19.48 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.02 billion
Optionable
Optionable
Beta
2.14
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Steven M. Klosk (Age 62)
    Pres, CEO & Director
  • Mr. Gregory P. Sargen (Age 53)
    Exec. VP of Corp. Devel. & Strategy and CFO
  • Mr. Shawn P. Cavanagh (Age 53)
    Exec. VP & COO
  • Ms. Samantha M. Hanley (Age 41)
    VP, Gen. Counsel & Corp. Sec.
  • Mr. James G. Farrell (Age 52)
    VP & Corp. Controller

CBM Stock Analysis - Frequently Asked Questions

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) announced its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to the consensus estimate of $132.78 million. Cambrex had a net margin of 5.96% and a trailing twelve-month return on equity of 5.38%. The business's revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.76 EPS.

What other stocks do shareholders of Cambrex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Illumina (ILMN), AbbVie (ABBV), NVIDIA (NVDA), CVS Health (CVS), Gilead Sciences (GILD), Intel (INTC), Walt Disney (DIS), Juno Therapeutics (JUNO) and Under Armour (UAA).

This page (NYSE:CBM) was last updated on 5/16/2024 by MarketBeat.com Staff

From Our Partners